| Name | Title | Contact Details |
|---|
Invisible is the operations innovation company transforming how companies are built and run. Our tech-enabled service harnesses our proprietary process orchestration platform, which seamlessly blends AI and automation with a global team of over 2000 highly-skilled agents. This integration eliminates execution bottlenecks and opens up new efficiency, scale, and growth possibilities for clients, delivering any operations capability better, faster, and cheaper than traditional 20th century services companies.
The Mutual Group is an innovative insurance services platform that provides a full suite of solutions designed to improve the operational efficiency and scalability of mutual insurance carriers.
Luxury mattresses, bed frames, sheets & pillows. 101-Night Mattress Sleep Trial. Free shipping, hassle-free returns & easy online shopping.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.